"Daratumumab/Carfilzomib Combo Effective In Lenalidomide-Refractory MM" - Leah Lawrence
Combining daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with lenalidomide-refractory relapsed multiple myeloma had promising efficacy and was generally well-tolerated, according to the results of a subgroup analysis of the MMY1001 trial. “Daratumumab with carfilzomib/dexamethasone is a safe and efficacious regimen regardless of prior lenalidomide exposure or refractoriness,” said Ajai Chari, MD, associate professor of medicine, hematology and medical oncology, director of clinical research in the multiple myeloma program and associate director of clinical research at the Mount Sinai Cancer Clinical Trials Office at the Icahn School of Medicine at Mount Sinai, who presented the results of the study at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1-5 in Chicago. “This study highlights the ability to do split dosing, particularly in community practice and to improve patient convenience,” said Dr. Chari.
- Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Icahn School of Medicine at Mount Sinai